MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ene.15573

Медицинская библиотека · European journal of neurology · 2022

Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

Beghi Ettore, Pupillo Elisabetta, Bianchi Elisa, Bonetto Valentina, Luotti Silvia, Pasetto Laura, Bendotti Caterina, Tortarolo Massimo, Sironi Francesca, Camporeale Laura, Sherman Alexander V, Paganoni Sabrina, Scognamiglio Ada, De Marchi Fabiola, Bongioanni Paolo, Del Carratore Renata, Caponnetto Claudia, Diamanti Luca, Martinelli Daniele, Calvo Andrea, Filosto Massimiliano, Padovani Alessandro, Piccinelli Stefano Cotti, Ricci Claudia, Dalla Giacoma Stefania, De Angelis Nicoletta, Inghilleri Maurizio, Spataro Rossella, La Bella Vincenzo, Logroscino Giancarlo, Lunetta Christian, Tarlarini Claudia, Mandrioli Jessica, Martinelli Ilaria, Simonini Cecilia, Zucchi Elisabetta, Monsurrò Maria Rosaria, Ricciardi Dario, Trojsi Francesca, Riva Nilo, Filippi Massimo, Simone Isabella Laura, Sorarù Gianni, Spera Cristina, Florio Lucia, Messina Sonia, Russo Massimo, Siciliano Gabriele, Conte Amelia, Saddi Maria Valeria, Carboni Nicola, Mazzini Letizia, RNS60-ALS Study Group

Рандомизированное исследованиеМногоцентровое исследованиеКлиническое исследование II фазыСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND AND PURPOSE: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with limited treatment options. RNS60 is an immunomodulatory and neuroprotective investigational product that has shown efficacy in animal models of ALS and other neurodegenerative diseases. Its administration has been safe and well tolerated in ALS subjects in previous early phase trials.

METHODS

This was a phase II, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial. Participants diagnosed with definite, probable or probable laboratory-supported ALS were assigned to receive RNS60 or placebo administered for 24 weeks intravenously (375 ml) once a week and via nebulization (4 ml/day) on non-infusion days, followed by an additional 24 weeks off-treatment. The primary objective was to measure the effects of RNS60 treatment on selected biomarkers of inflammation and neurodegeneration in peripheral blood. Secondary objectives were to measure the effect of RNS60 on functional impairment (ALS Functional Rating Scale-Revised), a measure of self-sufficiency, respiratory function (forced vital capacity, FVC), quality of life (ALS Assessment Questionnaire-40, ALSAQ-40) and survival. Tolerability and safety were assessed.

RESULTS

Seventy-four participants were assigned to RNS60 and 73 to placebo. Assessed biomarkers did not differ between arms. The mean rate of decline in FVC and the eating and drinking domain of ALSAQ-40 was slower in the RNS60 arm (FVC, difference 0.41 per week, standard error 0.16, p = 0.0101; ALSAQ-40, difference -0.19 per week, standard error 0.10, p = 0.0319). Adverse events were similar in the two arms. In a post hoc analysis, neurofilament light chain increased over time in bulbar onset placebo participants whilst remaining stable in those treated with RNS60.

CONCLUSIONS

The positive effects of RNS60 on selected measures of respiratory and bulbar function warrant further investigation.

Для цитирования: Beghi Ettore, Pupillo Elisabetta, Bianchi Elisa, Bonetto Valentina, Luotti Silvia, Pasetto Laura, Bendotti Caterina, Tortarolo Massimo, Sironi Francesca, Camporeale Laura, Sherman Alexander V, Paganoni Sabrina, Scognamiglio Ada, De Marchi Fabiola, Bongioanni Paolo, Del Carratore Renata, Caponnetto Claudia, Diamanti Luca, Martinelli Daniele, Calvo Andrea, Filosto Massimiliano, Padovani Alessandro, Piccinelli Stefano Cotti, Ricci Claudia, Dalla Giacoma Stefania, De Angelis Nicoletta, Inghilleri Maurizio, Spataro Rossella, La Bella Vincenzo, Logroscino Giancarlo, Lunetta Christian, Tarlarini Claudia, Mandrioli Jessica, Martinelli Ilaria, Simonini Cecilia, Zucchi Elisabetta, Monsurrò Maria Rosaria, Ricciardi Dario, Trojsi Francesca, Riva Nilo, Filippi Massimo, Simone Isabella Laura, Sorarù Gianni, Spera Cristina, Florio Lucia, Messina Sonia, Russo Massimo, Siciliano Gabriele, Conte Amelia, Saddi Maria Valeria, Carboni Nicola, Mazzini Letizia, RNS60-ALS Study Group. Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial.. European journal of neurology. 2022. DOI: 10.1111/ene.15573.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.